期刊文献+

临床试验缺失数据的统计学考量 被引量:6

Statistical considerations on missing data in clinical trials
原文传递
导出
摘要 缺失数据是临床试验中常见的重要问题,可能引起试验结果难于解释,甚至影响整个试验的推断和结论,但目前在国内临床研究中尚未引起足够的重视。实际应用中,申请人对待缺失数据的处理存在盲目应用统计学方法的现象,给新药安全有效性的评价和确证带来诸多困难。本文针对三个实际案例进行深入地阐述和分析,探讨对缺失数据的预防、估计量的选择、缺失数据的统计分析方法以及敏感性分析等,以期有助于申请人在临床试验中加强对缺失数据预防和处理方法的重视。 Missing data is a common and important issue in clinical trials. It could make the results difficult to be explained,even influence the inference and conclusion of the trial. Currently,not enough emphasis has been given to the problem in China. In the real world of statistical operation in dealing with clinical trial missing data,sponsors often applied various methods without any rational,which introduced many difficulties for evaluating and confirming the safety and efficacy of new drugs. In this paper,three real cases were specifically brought out for illustration and analysis,meanwhile,the prevention of missing data,the choice of esti-mator,statistical analysis methods and sensitivity analysis were also discussed. The aim is to attract the sponsors to focus attention on prevention and treatment of missing data in clinical trials.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2016年第5期469-472,共4页 The Chinese Journal of Clinical Pharmacology
关键词 临床试验 缺失数据 统计学 clinical trial missing data statistics
  • 相关文献

参考文献15

  • 1LITTLE R J, DAGOSTINO R, COHEN M L, et al. The prevention and treatment of missing data in clinical trials[J].N Engl J Med,2012,367(14):1355-1360. 被引量:1
  • 2CARPENTER J R, KENWARD M G. Missing data in randomised controlled trials - a practical guide[M]. Birmingham: National In- stitute for Health Research,2008:13-20. 被引量:1
  • 3ALr M W, TALUKDER E. Analysis of longitudinal binary data with missing data due to dropouts[J]. J Biopharm Stat,2005 ,15(6):993-1007. 被引量:1
  • 4FDA. Statistical review and evaluation ; application number 0224060rigl8000[EB/OL]. Washington: FDA, 2011-02-24[2015-07-30]. http://www. accessdata. fda. gov/drugsatfda_ docs/nda/2011/022406 Origl s000StatR. pdf. 被引量:1
  • 5KRANTZ M J,KAUL S. The ATLAS ACS 2-TIMl 51 trial and the burden of missing data:(Anti-Xa Therapy to Lower Caitiiovascu- lar Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-ttfombolysis In Myocardial Infarction 51)[J]. JAm Coll Cardiol, 2013,62(9):711-781. 被引量:1
  • 6YAN X, LEE S, LI N. Missing data Iiandling methods in medical de- vice clinical trials[J]. J Biopharm Stat, 2009,19(6):1085-1098. 被引量:1
  • 7FDA. Pulmonary-allergy drugs advisory committee meeting [EB/OL]. Washington: FDA, 2013-03-07[2015-07-30]. http://www. fda. gov/downloads/AdvisoryCommittees/Commit- teesMeetingMateriais/Drugs/Pulmonary-AllergyDrugsAdvisory- Committee/UCM336995. pdf. 被引量:1
  • 8FDA. Statistical review and evaluation : application number 2031880rigl8000[EB/OL]. Washington: FDA, 2012-04-18[2015-07-30]. http://www. accessdata. fda. gov/drugsatfda_ docs/nda/2012/203188 Origl s000StatR. pdf. 被引量:1
  • 9LEWIS JA. Statistical principles for clinical trials(ICH E9): an introductory note on an international guideline[J]. Stat Med,1999,18(15):1903-1942. 被引量:1
  • 10Committee for Medicinal Products for Human Use. Guideline on missing data in confirmatory clinical trials[EB/OL]. London : European Medicines Agency, 2009-03-23[2015-07-30]. http://www. emea. europa. eu. 被引量:1

同被引文献23

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部